The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy

During the last decade, immune checkpoint inhibition (ICI) has become a pillar of cancer therapy. Antibodies targeting CTLA-4 or PD-1/PD-L1 have been approved in several malignancies, with thousands of clinical trials currently underway. While the majority of cancer immunotherapies have traditionall...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jongdae, Lozano-Ruiz, Beatriz, Yang, Fengyuan Mandy, Fan, Dengxia Denise, Shen, Liya, González-Navajas, Jose M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994325/
https://www.ncbi.nlm.nih.gov/pubmed/33777008
http://dx.doi.org/10.3389/fimmu.2021.625667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994325/
https://www.ncbi.nlm.nih.gov/pubmed/33777008
http://dx.doi.org/10.3389/fimmu.2021.625667

Ejemplares similares